Cargando…
A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer
Triple negative (TNBCs) and the closely related Basal-like (BLBCs) breast cancers are a loosely defined collection of cancers with poor clinical outcomes. Both show strong similarities with BRCA1-mutant breast cancers and BRCA1 dysfunction, or ‘BRCAness’, is observed in a large proportion of sporadi...
Autores principales: | Buckley, Niamh E., Haddock, Paula, De Matos Simoes, Ricardo, Parkes, Eileen, Irwin, Gareth, Emmert-Streib, Frank, McQuaid, Stephen, Kennedy, Richard, Mullan, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991425/ https://www.ncbi.nlm.nih.gov/pubmed/26943587 http://dx.doi.org/10.18632/oncotarget.7865 |
Ejemplares similares
-
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
por: Mullan, Paul B., et al.
Publicado: (2019) -
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer
por: Elkashif, Ahmed, et al.
Publicado: (2020) -
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer
por: Knowlson, Catherine, et al.
Publicado: (2020) -
Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)
por: Orr, Katy, et al.
Publicado: (2016) -
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
por: Humphries, Matthew P., et al.
Publicado: (2018)